Finally Time For Investors to Buy? J.P. Morgan Upgrades PTC Therapeutics (NASDAQ:PTCT), With $15.0 Target

February 24, 2018 - By Michael Collier

  Finally Time For Investors to Buy? J.P. Morgan Upgrades PTC Therapeutics (NASDAQ:PTCT), With $15.0 Target

Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported.

Metropolitan Life Insurance owns 27,393 shares. Fisher Asset Mngmt Ltd Liability Corporation holds 0% or 173,045 shares. State Street has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). 31,080 were reported by Barclays Public Llc. Hanseatic stated it has 105 shares or 0% of all its holdings. Geode Capital Ltd Liability Corp has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). California State Teachers Retirement Sys holds 64,160 shares or 0% of its portfolio. Royal Retail Bank Of Canada holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 10,972 shares. Legal & General Group Inc Incorporated Public Llc holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 9,414 shares. Los Angeles Capital Mgmt & Equity Rech Inc accumulated 11,460 shares. Quantbot Technologies L P reported 7,502 shares or 0.01% of all its holdings. Jane Street Group Inc Incorporated Ltd Co holds 0.01% or 78,768 shares. Quantitative Inv Ltd Limited Liability Company reported 0.07% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Swiss Bancorporation invested in 65,565 shares or 0% of the stock. Ameritas Inv Ptnrs holds 2,612 shares or 0% of its portfolio.

Since January 3, 2018, it had 0 insider buys, and 4 selling transactions for $61,523 activity. 2,230 shares were sold by Peltz Stuart Walter, worth $40,207 on Friday, January 5. The insider Almstead Neil Gregory sold 77 shares worth $1,361.

PTC Therapeutics (NASDAQ:PTCT) Stock Upgrade

In an analyst note issued to clients and investors earlier today, J.P. Morgan upped shares of PTC Therapeutics (NASDAQ:PTCT) to a Hold. Analysts currently have a $15.0 target price per share on the shares. J.P. Morgan’s target price per share suggests a ppossible downside of -41.22 % from the last stock close of the stock.

Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTC Therapeutics, Inc. shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported.

Metropolitan Life Insurance owns 27,393 shares. Fisher Asset Mngmt Ltd Liability Corporation holds 0% or 173,045 shares. State Street has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). 31,080 were reported by Barclays Public Llc. Hanseatic stated it has 105 shares or 0% of all its holdings. Geode Capital Ltd Liability Corp has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). California State Teachers Retirement Sys holds 64,160 shares or 0% of its portfolio. Royal Retail Bank Of Canada holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 10,972 shares. Legal & General Group Inc Incorporated Public Llc holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 9,414 shares. Los Angeles Capital Mgmt & Equity Rech Inc accumulated 11,460 shares. Quantbot Technologies L P reported 7,502 shares or 0.01% of all its holdings. Jane Street Group Inc Incorporated Ltd Co holds 0.01% or 78,768 shares. Quantitative Inv Ltd Limited Liability Company reported 0.07% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Swiss Bancorporation invested in 65,565 shares or 0% of the stock. Ameritas Inv Ptnrs holds 2,612 shares or 0% of its portfolio.

Since January 3, 2018, it had 0 insider buys, and 4 selling transactions for $61,523 activity. 2,230 shares were sold by Peltz Stuart Walter, worth $40,207 on Friday, January 5. The insider Almstead Neil Gregory sold 77 shares worth $1,361.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics has $135 highest and $6 lowest target. $35.30’s average target is 38.32% above currents $25.52 stock price. PTC Therapeutics had 36 analyst reports since July 31, 2015 according to SRatingsIntel. As per Thursday, February 22, the company rating was maintained by Citigroup. RBC Capital Markets maintained PTC Therapeutics, Inc. (NASDAQ:PTCT) on Friday, October 16 with “Outperform” rating. The firm has “Sell” rating by Bank of America given on Thursday, October 26. The firm has “Neutral” rating given on Tuesday, February 23 by JP Morgan. The stock has “Hold” rating by RBC Capital Markets on Monday, January 29. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, January 20 report. RBC Capital Markets maintained the stock with “Sector Perform” rating in Friday, November 11 report. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, July 5 report. The company was maintained on Thursday, February 25 by Oppenheimer. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Buy” rating by Citigroup on Tuesday, August 25.

The stock decreased 0.55% or $0.14 during the last trading session, reaching $25.52. About 573,229 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since February 24, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on March, 15. They expect $-0.02 earnings per share, up 97.44 % or $0.76 from last year’s $-0.78 per share. After $-0.67 actual earnings per share reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -97.01 % EPS growth.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company has market cap of $1.06 billion. The companyÂ’s lead product is Translarna , for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It currently has negative earnings. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy.

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Streetinsider.com which released: “PTC Therapeutics (PTCT) Says FDA Denied Appeal of CRL in Relation to NDA for …” on February 20, 2018, also Prnewswire.com published article titled: “PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare …”, Streetinsider.com published: “PTC Therapeutics (PTCT) Reports Preliminary Data from FIREFISH trial in Type 1 …” on January 27, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: Prnewswire.com and their article: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: